Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503925 | 1.00 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL697850 | 1.00 | JAK2 (0.55) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL3152405 | 0.93 | USP30 (0.56) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL3152395 | 0.93 | USP30 (0.56) | JAK2JAK1PRMT5WDR77USP30 | |
| SCHEMBL12607067 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL12607070 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL29117319 | 0.93 | PRMT5 (0.56) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL3249107 | 0.92 | STS (0.58) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL9938446 | 0.90 | PRMT5 (0.51) | JAK2JAK1PRMT5WDR77STS | |
| SCHEMBL16903418 | 0.90 | JAK2 (0.53) | JAK2JAK1PRMT5WDR77STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9586899-B2 | Synthetic process for aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2017-03-07 | — | — | US | disclosed |
| WO-2017017630-A1 | NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-02 | — | — | WO | disclosed |
| CN-105153133-A | New compound for conversion of auricular fibrillation, preparation method, pharmaceutical composition and application | ANHUI YIXINMING PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-12-16 | — | — | CN | disclosed |
| EP-1950198-B1 | PROCESS FOR PRODUCTION OF BENZYLOXYPYRROLIDINE DERIVATIVE, AND PROCESS FOR PRODUCTION OF HYDROCHLORIDE SALT POWDER OF OPTICALLY ACTIVE BENZYLOXYPYRROLIDINE DERIVATIVE | TORAY FINECHEMICALS CO LTD (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8247578-B2 | Process for production of aralkyloxypyrrolidine derivative | KANEKA CORPORATION (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-8058304-B2 | Merged ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20060247300-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2006-11-02 | — | — | US | disclosed |
| EP-1666459-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2006-06-07 | — | — | EP | disclosed |
| EP-1560812-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2006-05-10 | — | — | EP | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1560812-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Cardiome Pharma Corp. (CA) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004099137-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2004-11-18 | — | — | WO | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | JAK2 524/4885JAK1 803/4885PRMT5 288/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | JAK2 3671/4885JAK1 3089/4885PRMT5 523/4885 |
| US-20060247300-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | JAK2 829/4885JAK1 3350/4885PRMT5 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.